Allergan PLC (NYSE:AGN) had its target price decreased by Mizuho from $293.00 to $273.00 in a research report sent to investors on Thursday morning. Mizuho currently has a buy rating on the stock.

Several other equities research analysts have also commented on the company. Leerink Swann upped their target price on Allergan PLC from $272.00 to $294.00 and gave the company an outperform rating in a research report on Wednesday, July 27th. Goldman Sachs Group Inc. restated a buy rating on shares of Allergan PLC in a research report on Monday, September 12th. JPMorgan Chase & Co. set a $325.00 target price on Allergan PLC and gave the company a buy rating in a research report on Friday, August 5th. Zacks Investment Research lowered Allergan PLC from a buy rating to a hold rating in a research report on Tuesday, July 26th. Finally, Barclays PLC restated an equal weight rating and set a $250.00 target price on shares of Allergan PLC in a research report on Monday, October 31st. Six equities research analysts have rated the stock with a hold rating and twenty have given a buy rating to the company. Allergan PLC has an average rating of Buy and a consensus price target of $289.11.

Shares of Allergan PLC (NYSE:AGN) traded down 2.53% during trading on Thursday, reaching $194.92. The company’s stock had a trading volume of 1,143,785 shares. Allergan PLC has a 12 month low of $186.34 and a 12 month high of $322.68. The company’s 50 day moving average price is $219.19 and its 200 day moving average price is $233.94. The firm has a market cap of $73.11 billion, a PE ratio of 5.47 and a beta of 1.08.

Allergan PLC (NYSE:AGN) last issued its earnings results on Wednesday, November 2nd. The company reported $3.32 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.65 by $0.33. Allergan PLC had a return on equity of 7.26% and a net margin of 93.74%. The firm earned $3.62 billion during the quarter, compared to analyst estimates of $3.73 billion. During the same period in the previous year, the company earned $3.48 EPS. Allergan PLC’s revenue for the quarter was up 4.4% on a year-over-year basis. On average, equities analysts predict that Allergan PLC will post $13.37 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 28th. Shareholders of record on Tuesday, February 28th will be given a dividend of $0.70 per share. This represents a $2.80 annualized dividend and a yield of 1.40%. This is a boost from Allergan PLC’s previous quarterly dividend of $0.05.

In other news, CFO Maria Teresa Hilado acquired 1,422 shares of the business’s stock in a transaction on Friday, November 11th. The shares were acquired at an average cost of $210.64 per share, with a total value of $299,530.08. Following the transaction, the chief financial officer now owns 12,659 shares in the company, valued at approximately $2,666,491.76. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 0.27% of the company’s stock.

Hedge funds have recently modified their holdings of the company. Balentine LLC boosted its stake in shares of Allergan PLC by 0.4% in the second quarter. Balentine LLC now owns 1,706 shares of the company’s stock worth $394,000 after buying an additional 7 shares in the last quarter. Motco boosted its stake in shares of Allergan PLC by 0.7% in the second quarter. Motco now owns 1,202 shares of the company’s stock worth $278,000 after buying an additional 8 shares in the last quarter. Wilbanks Smith & Thomas Asset Management LLC boosted its stake in shares of Allergan PLC by 0.7% in the third quarter. Wilbanks Smith & Thomas Asset Management LLC now owns 1,351 shares of the company’s stock worth $311,000 after buying an additional 9 shares in the last quarter. Pure Financial Advisors Inc. boosted its stake in shares of Allergan PLC by 0.4% in the second quarter. Pure Financial Advisors Inc. now owns 2,596 shares of the company’s stock worth $600,000 after buying an additional 10 shares in the last quarter. Finally, Apriem Advisors boosted its stake in shares of Allergan PLC by 1.2% in the third quarter. Apriem Advisors now owns 1,021 shares of the company’s stock worth $235,000 after buying an additional 12 shares in the last quarter. 85.20% of the stock is currently owned by hedge funds and other institutional investors.

Allergan PLC Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

5 Day Chart for NYSE:AGN

Receive News & Stock Ratings for Allergan PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC and related stocks with our FREE daily email newsletter.